Kinetically Guided Neoadjuvant Chemoradiotherapy Based on 5-Fluorouracil in Patients with Locally Advanced Rectal Cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F15%3A10315478" target="_blank" >RIV/00216208:11150/15:10315478 - isvavai.cz</a>
Alternative codes found
RIV/00179906:_____/15:10315478
Result on the web
<a href="http://dx.doi.org/10.1007/s40262-014-0216-4" target="_blank" >http://dx.doi.org/10.1007/s40262-014-0216-4</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s40262-014-0216-4" target="_blank" >10.1007/s40262-014-0216-4</a>
Alternative languages
Result language
angličtina
Original language name
Kinetically Guided Neoadjuvant Chemoradiotherapy Based on 5-Fluorouracil in Patients with Locally Advanced Rectal Cancer
Original language description
This study estimated patients' early response following neoadjuvant chemoradiotherapy (CHRT) of locally advanced rectal cancer based on 5-fluorouracil (5-FU). The target was to achieve pathological complete response and toxicities of grade LESS-THAN OR EQUAL TO2, using individual dosing predicted according to the steady-state plasma concentration (Css) and pharmacokinetic parameters of 5-FU: the area under the time-concentration curve at steady state (AUC) and clearance (CL). This open-label prospectivestudy enrolled 33 adult patients treated with 5-FU administered as a continuous intravenous infusion over 4-5 weeks, as follows: in Group 1a (N = 6), the patients received a standard dose of 300 mg/m2/24 h. In Group 1b (N = 7), the patients were treatedwith an escalated dose of 400-1,000 mg/m2/24 h. In Group 2 (N = 20), the patients were given dosing kinetically guided in order to reach the target range of 5-FU Css 50-100 ?g/L. Tolerability was tested according to Common Terminology Cr
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NS9693" target="_blank" >NS9693: Individual 5-fluorouracil dose individualization in patients with colorectal cancer</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Clinical Pharmacokinetics
ISSN
0312-5963
e-ISSN
—
Volume of the periodical
54
Issue of the periodical within the volume
5
Country of publishing house
NZ - NEW ZEALAND
Number of pages
13
Pages from-to
503-515
UT code for WoS article
000355338600004
EID of the result in the Scopus database
2-s2.0-84939965747